Notable Representations

SRS v. Alexion Pharmaceuticals, Inc. (Del. Chancery). Lead trial counsel for the selling shareholders of Syntimmune, Inc. in a post-merger earnout dispute. After a seven-day bench trial, the Court entered judgment for $130 million for failure to pay a milestone when due. The Court further ruled that the defendant had breached its obligation to use commercially reasonable efforts to develop the new product candidate when it terminated the development program. Further briefing on causation and damages will follow.

Regenxbio Inc. et al. v. Sarepta Therapeutics, Inc. and Wilson Wolf Mfg. v. Sarepta Therapeutics, Inc. (D. Del). Lead counsel for Sarepta in the defense of patent litigations arising out of Sarepta’s development and clinical study of lifesaving gene therapy treatment for Duchenne Muscular Dystrophy. Judgment entered for Sarepta finding that the patent in suit was invalid due to unpatentable subject matter.

Lockton Companies, LLC in its successful motion for a preliminary injunction against Alliant Insurance Services arising out of a corporate raid termed the “Worst (Non-Lawyer) Lateral Acquisition Ever” by the AmLaw Litigation Daily.